½ 2002 ju

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ſ

(use as many sheets as necessary)

Comple	ete if Known
Application Number	10/084,706
Filing Date	February 26, 2002
First Named Inventor	Rasmussen, et al.
Group Art Unit	1647
Examiner Name	J. Seharaseyon
Attorney Docket Number	0228us410

		U.S. Patent Doc		S. PATENT DOCUMENTS  Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
						RECEIVE
						DEC 1 2 70 07
						TECH CENTER 160

				FOREIGI	N PATENT DOCUMEN	TS		
<b>)</b>		Foreign Patent Document				Date of Publication	Pages, Columns, Lines,	
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Т
<i>~</i> \$>	1	EP	0 287 075	B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988	·	X
<b>8</b>	2	EP	0 287 075 (English language translation of document AY)	BZ	Dr. Rentschler Biotechnologie GmbH	10/19/1988		
<i>₹</i> 85	3	wo	01/15736	A2	Maxygen ApS	03/08/2001		
	ļ							

	<b></b>	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	т
	4	O'CONNELL, et al., "The Influence of Flanking Sequences on O-Glycosylation", Biochemical and Biophysical Research Communications, 1991, pp. 1024-1030, 180:2.	

					1	<u> </u>	
Examiner	Q\ \ (	<u>,</u>	Date	3	2/11	50	
Signature	Ure		Considered		21	_/ 	
					•		

TEXAMINER: Initial if reference of insidered, whether condition is to conformance with MPEP 669. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PAPEL

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

022805410

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

09/648,569 10/084 **Application Number** Filing Date August 25, 2000 First Named Inventor A. H. Pedersen **Group Art Unit** 1647 **Examiner Name** J. Seharaseyon Attorney Docket Number

<del>-0202us810 -</del>

Complete if Known

(use as many sheets as necessary)

Examiner Initials	Cite No.	U.S. Patent De	ocument	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, lines,
		Number	Kind Code (if known)		Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
\$	1	5,206,344		Katre et al.	04/27/1993	
1	2	5,738,846		Greenwald et al.	04/14/1998	

		τ	Foreign Patent Docu		N PATENT DOCUMEN	Date of Publication	Pages, Columns, Lines,	
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document  MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	т
The state of the s	3	EP	0 370 205	A2	Kyowa Hakko Kogyo Co., Ltd.	05/30/1990		
	4	EP	0 529 300	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93	RECEIV	Ě
	5	EP	0 529 300 (English language translation of document #4)	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93	NOV 1 9 2	008
	6	wo	95/27502	A1	Research Develop- ment Foundation	10/19/1995	TEOHOLINE	
}	7	wo	98/35026	A1	Novo Nordisk A/S	08/13/1998		
9	8	wo	99/55377	A2	Applied Research Systems	11/04/1999		

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	_
-M	9	Derwent-Abstract-012152872-for-WO-98/48018, a German-publication cited in previous IDS Form-1449.	
12	10	Derwent_Abstract 009442954 for EP 539 300, a French publication cited in previous IDS Form-1449.	
			†

Examiner (/)\		Date	2/11/2
Signature			<13111/2
Signature :		Considered	
	\		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

tute for form 1449A-B/PTO

APARENT

(Modified) PTO/SB/08A-B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

## INFORMATION DISCLOSURE COPY STATEMENT BY APPLICANT

~^ \ \ \ '	
LaOre	omplete if Known
Application Number	09/648,569 - 10/084 706
Filing Date	August 25, 2000 03/26/02
First Named Inventor	Anders, Hjelholt Pedersen Rassmuss
Group Art Unit	1639-1647
Examiner Name	Unassigned J. Scharaseyon
Attorney Docket Number	31-107600US C228US410

	3			Application Number	Approved for use unough	
ŞW	stitute fo	or form 1449A-B/PTO		SOM.	Complete if Known	
73 TAR		ATION DISCLOSUR ENT BY APPLICANT	-ol	Application Number		10/084 706
INI	FORM	ATION DISCLOSUR	EC:Or '	Filing Date	August 25, 2000	0.2/26/02
ST	ATEM	ENT BY APPLICANT	<sub>r</sub> O	First Named Inventor	Anders, Hjelholi	Pedersen Rasmusse
				Group Art Unit	1633-1647	
				Examiner Name	Unassigned	J. Scharaseyon
_	(use as	s many sheets as necessa	ary)	Attorney Docket Number	31-107800US	022805410
			U.	S. PATENT DOCUMENTS		
Examiner	Cite	. U.S. Patent Docu	ment Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, lines, Where Relevant Passages
Initials	No.	Number	(it known)	Ched Document	MM-DD-YYYY	or Relevant Figures Appeal
12	AA	4,588,585		Mark et al.	05-13-1986	
<u> </u>		4,:/00,:/0:/				<del> </del>
}	AB	4,686,191		Itoh et al.	08-11-1987	
	AC	1.760.222		Bell et al.	09-06-1988	
	1 40	4,769,233		Dell'et al.	09-00-1900	
- 1	AD	4,904,584		Shaw	02-27-1990	[
	+			<u> </u>	0.4.00.4.000	
ł	AE	4,914,033		Bell et al.	04-03-1990	
	AF	4,917,888		Katre et al.	04-17-1990	
	<del>  ' ''</del>	4,717,000		114.10 01 4.1.	0	- SECFIVED
- 1	AG	4,966,843		McCormick et al.	10-30-1990	1,002
	1	5 210 002		Constrict of	00.00.1002	NOV 1 5 2002
	AH	5,218,092	,	Sasaki et al.	08-06-1993	MOATA
	AI	5,376,567		McCormick et al.	12-27-1994	
-	<del> </del>					TECH CENTER 1600/2
	AJ	5,382,657		Hoffmann-La Roche Inc.	01-17-1995	
	AK	5 545 722		Goelz et al.	08-13-1996	
	AIN	5,545,723			00-13-1330	
<b>/</b> /	AL	5,795,779		McCormick et al.	08-18-1998	1

	Υ	T	Foreign Patent Docu		N PATENT DOCUMEN	Date of Publication	Pages, Columns, Lines,	Т
Examin er Initials	Cite No	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T
~}\\	AM	wo	95/25170		Biogen, Inc.	09-21-1995		
	AN	wo	98/48018		Fraun-Hoter- Gesellschaft Zur Forderung Der Angewandten	10-29-1998		
	AO	wo	99/03887		Bolder Biotechnology	01-28-1999		
	AP	wo	99/55377		Applied Research	11.04.1990		1
	· · .	. <b>.</b>	196 294		immunex Corporation	12-29-1999	<u>:</u>	•
1	AR	; wo	00/23114	:	, Biogen, Inc.	; 04-27-2000		!
	i		•				i e	

	<u> </u>				/
Examiner Signature	Deli	Date Considered	3/21	05	

<sup>\*</sup>EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3 200 (3)	PARENT	(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031
THIS ostitute for form 1449A-B/PTO	O	Complete if Known
NY.	Application Number	09/648,569 - 10/084 706
INFORMATION DISCLOSUREO STATEMENT BY APPLICANT	Filing Date	August 25, 2000 02/26/02
STATEMENT BY APPLICANT	First Named Inventor	Anders, Hjolholt Pedersen- Kusmussian
	Group Art Unit	1633- 1647
	Examiner Name	Unassigned J. Scharascyon
(use as many sheets as necessary)	Attorney Docket Number	21-107600US - 0228 US 4/0

100	, ,	AS	wo	00/23472	Biogen, Inc.	04-27-2000	
	7	AT	wo	00/26354	Novo Nordisk	05-11-2000	·
	,	AU	EP	083 069	Kyowa Hakko Kogyo Co., Ltd.	09-16-1987	RECEIVED
	1	AV	EP	041 313	Biogen, Inc.	09-12-1990	THE CENT OF
	1	AW	EP	229 108	Cetus Corporation	12-27-1990	NOV 1 5 2002
	1	ΑX	EP	260 350	Cetus Corporation	02-12-1992	TECH CENTER 1600/2
	A	ΑY	EP	287 075	Arzeneimittelforschung /Drug Research	01-18-1995	
	1	ΑZ	EP	539 300	Philippe Thiriet	02-07-1996	
1	J E	ЗА	EP	593 868	Hoffmann-La Roche Inc.	04-15-1998	

	1	OTHER PRIOR ART - NON PATECNT LITERATURE DOCUMENTS	· · · · · ·
Examin er Initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
\$	ВВ	Fierlbeck et al., "Neutralising interferon β antibodies in melanoma patients treated with recombinant and natural interferon β" Cancer Immunol Immunother (1994) 39:263-268	
	ВС	Karpusas et al., "The Structure of Human Interferon- β: Implications for activity" <u>CMLS</u> 54 (1998) 1203-1216	
	BD	Karpusas <i>et al.</i> "The crystal structure of human interferon β at 2.2 A resolution" Proc. Nat. Acad. Sci. USA (1997) 94:11813-11818	
	BE	Mayorga et al., "Antibodies to Commercially Available Interferon-Bet Molecules in Multipule Sclerosis Patients Treated with Natural Interferon-Beta" <a href="Int. Arch. Allery Immunol">Int. Arch. Allery Immunol</a> 1999; 118:368-371	
	BF	Munschauer et al., "Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multipule Sclerosis" Clinical Therapeutics vol. 19, No. 5, 1997 883-893	
J	₽Ç.	a linear epitope: Analysis by synthetic peptide mapping." Proc. Nati. Acad. Sci. USA vol. 88, pp. 4040-4044 May 1991	

Examiner	
Signature	

Date Considered

<sup>15.2</sup> AMINER That all if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in informance and not considered. Include copy of this form with next communication to applicant.

TO STATE OF THE PARTY OF THE PA	OM PARENT	(Modified) PTO/SB/08A-B (10-96) approved for use through 10/31/99. OMB 0651-0031
Substrate for form 1449A-B/PTO		omplete if Known
TRANS	Application Number	09/648,569- 10/084,766
INFORMATION DISCLOSURE CO.	Filing Date	August 25, 2000 02/26/02
STATEMENT BY APPLICANT	First Named Inventor	Anders, Hjelholt Pedersen Rasmussen
	Group Art Unit	1633 /647
·	Examiner Name	Unassigned J. Scharascyon
(use as many sheets as necessary)	Attorney Docket Number	-31-107600US 0228US410

2	3	вн	Rudick et al., "Incidence and significance of neutralizing antibodies to interferon beta-1a in multipule sclerosis" Neurology May 1889, 50: 1266-1272
		ВІ	Runkel et al., "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- β (IFN- β) Pharmaceutical Research vol. 15, No 4, 1998, 641-649
		ВJ	Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between α and β Type I Interferons Explored by Mutational Analysis" 273, No. 14, pp. 8003-8008
		вк	Senda et al., "Refined Crystal Structure of Recombinant Murine Interferon- β at 2.15 A Resolution" J. Mil. Biol. (1995) 253, 187-207
		BL	Stewart et al, DNA "Chemical Mutagenesis of Human Interferon- \( \beta \): Construction,  Expression in E. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations  Vol 6 no 2 1987 p119-128
		ВМ	Tanigunchi, et al., "The nucleotide sequence of human fibroblast interferon cDNA"  Gene 10 (1980) 11-15
\ \ \	j	BN	Yong et al., "Interferon beta in the treatment of multiple sclerosis" Neurology 1998; 51: 682-689

RECEIVED NOV 1 5 2002 TECH CENTER 1600:290(

Examiner Signature

Date Considered 23

15 NAMINER - Initial traference considered, whether or not obtain is in conformance with MPEP 609. Draw line through citation if not in int, imande and not considered. Include copy of this form with next communication to applicant.